JP2019519208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519208A5 JP2019519208A5 JP2018559329A JP2018559329A JP2019519208A5 JP 2019519208 A5 JP2019519208 A5 JP 2019519208A5 JP 2018559329 A JP2018559329 A JP 2018559329A JP 2018559329 A JP2018559329 A JP 2018559329A JP 2019519208 A5 JP2019519208 A5 JP 2019519208A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- antibody
- cell
- ctla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201603721T | 2016-05-10 | ||
| SG10201603721TA SG10201603721TA (en) | 2016-05-10 | 2016-05-10 | Anti-CTLA-4 Antibodies |
| PCT/EP2017/058956 WO2017194265A1 (en) | 2016-05-10 | 2017-04-13 | Anti-CTLA-4 Antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519208A JP2019519208A (ja) | 2019-07-11 |
| JP2019519208A5 true JP2019519208A5 (enExample) | 2019-08-22 |
| JP6650537B2 JP6650537B2 (ja) | 2020-02-19 |
Family
ID=58609383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559329A Active JP6650537B2 (ja) | 2016-05-10 | 2017-04-13 | 抗ｃｔｌａ−４抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9758583B2 (enExample) |
| EP (1) | EP3455255B1 (enExample) |
| JP (1) | JP6650537B2 (enExample) |
| KR (1) | KR20190015715A (enExample) |
| CN (1) | CN109563165B (enExample) |
| AU (1) | AU2017262448A1 (enExample) |
| CA (1) | CA3023787A1 (enExample) |
| SG (2) | SG10201603721TA (enExample) |
| TW (1) | TW201739763A (enExample) |
| WO (1) | WO2017194265A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8835419B2 (en) | 2011-12-01 | 2014-09-16 | Chemocentryx, Inc. | Substituted anilines as CCR(4) antagonists |
| WO2016177682A1 (en) | 2015-05-06 | 2016-11-10 | Snipr Technologies Limited | Altering microbial populations & modifying microbiota |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| SG10201603721TA (en) * | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| IL307242B1 (en) | 2016-12-07 | 2026-07-01 | Agenus Inc | Anti-CTLA-4 antibodies and methods of using them |
| CN111511762B (zh) | 2017-08-21 | 2025-05-06 | 天演药业公司 | 抗cd137分子及其用途 |
| CA3073984A1 (en) * | 2017-09-21 | 2019-03-28 | Eucure (Beijing) Biopharma Co., Ltd | Anti-ctla4 antibodies and uses thereof |
| CN111954680B (zh) | 2017-11-10 | 2024-03-15 | 新加坡科技研究局 | IL2Rβ/共同γ链抗体 |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| ES3068176T3 (en) * | 2018-02-12 | 2026-05-28 | Massachusetts Gen Hospital | Chimeric antigen receptor t cells targeting the tumor microenvironment |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| CA3100349A1 (en) * | 2018-05-17 | 2019-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Receptor inhibition by phosphatase recruitment |
| MX2021002302A (es) | 2018-08-29 | 2021-04-28 | Chemocentryx Inc | Terapia de combinacion usando antagonistas de receptor de quimiocina c-c 4 (ccr4) y uno o mas inhibidores de punto de control. |
| MX2021005048A (es) | 2018-10-31 | 2021-09-08 | Bioatla Inc | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. |
| WO2020094834A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| WO2020094836A1 (en) | 2018-11-09 | 2020-05-14 | Euchloe Bio Pte. Ltd. | Il2rbeta/common gamma chain antibodies |
| WO2020127377A1 (en) | 2018-12-21 | 2020-06-25 | Ose Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| CN114008071B (zh) | 2018-12-27 | 2025-01-21 | 吉加根公司 | 抗ctla-4结合蛋白及其使用方法 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| CN110343180B (zh) * | 2019-07-25 | 2021-03-30 | 北京免疫方舟医药科技有限公司 | 抗ctla-4抗体及其应用 |
| TW202136287A (zh) | 2019-12-17 | 2021-10-01 | 法商Ｏｓｅ免疫治療公司 | 包含il-7變體之雙官能分子 |
| US12595307B2 (en) | 2020-06-11 | 2026-04-07 | Nantbio, Inc. | Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors |
| US20230265192A1 (en) * | 2020-07-02 | 2023-08-24 | Gigagen, Inc. | Anti-ctla-4 binding proteins and methods of use thereof |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022169269A1 (ko) * | 2021-02-03 | 2022-08-11 | 주식회사 유틸렉스 | 항 ctla-4 항체 및 이의 용도 |
| RU2757418C1 (ru) * | 2021-03-04 | 2021-10-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный университет" | Тетрадекапептидный антагонист взаимодействия CTLA-4 c B7-1 |
| MX2023011964A (es) | 2021-04-09 | 2024-01-08 | Ose Immunotherapeutics | Nuevo andamio para moléculas bifuncionales con propiedades mejoradas. |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| EP4565610A1 (en) | 2022-08-02 | 2025-06-11 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| JP2026512425A (ja) | 2023-03-30 | 2026-04-16 | オーエスイー・イミュノセラピューティクス | 免疫細胞増強分子の発現のための活性化免疫細胞に標的化された脂質ベースのナノ粒子及びその使用 |
| WO2024200820A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2025137321A1 (en) * | 2023-12-21 | 2025-06-26 | Fenwal, Inc. | System and method for affinity cell selection |
| EP4599843A1 (en) | 2024-02-09 | 2025-08-13 | Fundació Institut de recerca de l'Hospital de la Santa Creu i Sant Pau | Car and modified cd200r combination |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE311895T1 (de) | 1992-05-26 | 2005-12-15 | Immunex Corp | Neue zytokine die cd30 binden |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
| EP1471938A4 (en) | 2002-01-09 | 2008-03-05 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST CD30 |
| MXPA06008700A (es) | 2004-02-06 | 2007-01-19 | Morphosys Ag | Anticuerpos anti-cd38 humanos y usos para los mismos. |
| CA2601417C (en) | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| KR20090058512A (ko) | 2006-08-04 | 2009-06-09 | 아스트라제네카 아베 | Ｅｒｂｂ2에 대한 인간 항체 |
| WO2008059491A1 (en) | 2006-11-13 | 2008-05-22 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating cancer using sirna molecules directed against cd24 |
| NZ579644A (en) | 2007-02-16 | 2012-05-25 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| AR069747A1 (es) | 2007-11-30 | 2010-02-17 | Medarex Inc | Conjugado anticuerpo monoclonal anti-b7h4- farmaco y metodos de utilizacion |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2011034660A1 (en) | 2009-09-16 | 2011-03-24 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| JP2013534813A (ja) | 2010-05-26 | 2013-09-09 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 抗ｃｄ１３３抗体一本鎖可変断片、及びこれらの使用 |
| LT2609118T (lt) | 2010-08-23 | 2017-04-25 | Board Of Regents, The University Of Texas System | Anti-ox40 antikūnai ir jų panaudojimo būdai |
| EP2703486B1 (en) | 2011-04-25 | 2018-03-07 | Daiichi Sankyo Company, Limited | Anti-b7-h3 antibody |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| WO2013048883A2 (en) | 2011-09-30 | 2013-04-04 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| US9422351B2 (en) | 2011-11-03 | 2016-08-23 | The Trustees Of The University Of Pennsylvania | Isolated B7-H4 specific compositions and methods of use thereof |
| CA2884704C (en) | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Vista modulators for diagnosis and treatment of cancer |
| EP2912063A1 (en) | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| AU2013361275B2 (en) | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
| WO2014130635A1 (en) | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| US9790282B2 (en) | 2013-03-25 | 2017-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD276 polypeptides, proteins, and chimeric antigen receptors |
| RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| US10273301B2 (en) | 2013-12-24 | 2019-04-30 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments |
| CN104974253A (zh) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | 抗ctla-4/pd-1双特异性抗体、其制备方法及应用 |
| SG10201603721TA (en) * | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
-
2016
- 2016-05-10 SG SG10201603721TA patent/SG10201603721TA/en unknown
-
2017
- 2017-04-13 WO PCT/EP2017/058956 patent/WO2017194265A1/en not_active Ceased
- 2017-04-13 AU AU2017262448A patent/AU2017262448A1/en not_active Abandoned
- 2017-04-13 US US15/486,468 patent/US9758583B2/en active Active
- 2017-04-13 JP JP2018559329A patent/JP6650537B2/ja active Active
- 2017-04-13 TW TW106112375A patent/TW201739763A/zh unknown
- 2017-04-13 CN CN201780029330.5A patent/CN109563165B/zh active Active
- 2017-04-13 EP EP17718870.3A patent/EP3455255B1/en active Active
- 2017-04-13 US US16/099,652 patent/US11267887B2/en active Active
- 2017-04-13 KR KR1020187035791A patent/KR20190015715A/ko not_active Ceased
- 2017-04-13 SG SG11201809857TA patent/SG11201809857TA/en unknown
- 2017-04-13 CA CA3023787A patent/CA3023787A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508475A5 (enExample) | ||
| US11690908B2 (en) | Use of endogenous viral vaccine in chimeric antigen receptor T cell therapy | |
| AU2021200091B2 (en) | Chimeric antigen receptor compositions | |
| JP2018500924A5 (enExample) | ||
| JP2017536111A5 (enExample) | ||
| JP2017538441A5 (enExample) | ||
| JP2018527912A5 (enExample) | ||
| JP6650537B2 (ja) | 抗ｃｔｌａ−４抗体 | |
| JP2024023317A (ja) | 二重特異性抗体の組成物及びその使用方法 | |
| RU2017116847A (ru) | Антитела к pd-1 | |
| JP2022514262A (ja) | 双子型免疫細胞エンゲージャー | |
| US20190358262A1 (en) | Methods for modulation of car-t cells | |
| CN111246882A (zh) | 抗il1rap抗体 | |
| CN112955179A (zh) | 拮抗性抗肿瘤坏死因子受体超家族多肽 | |
| FI3250592T3 (fi) | Transtyretiinin vastaisia vasta-aineita | |
| JP2023073965A (ja) | 癌関連免疫抑制阻害剤 | |
| JP2023547313A5 (enExample) | ||
| HK40104763A (en) | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies | |
| WO2024182541A1 (en) | Molecules that bind to b-cell activating factor receptor polypeptides | |
| RU2024115283A (ru) | Композиции vcar и способы применения |